36 results on '"Lescrauwaet B"'
Search Results
2. PSS26 - COST EFFECTIVENESS OF OCRIPLASMIN FOR TREATMENT OF SYMPTOMATIC VITREOMACULAR ADHESION IN THE UNITED STATES
3. PSS8 - Prognostic and Treatment Effect Modifying Baseline Factors for Visual Functioning Response in Non-Infectious Uveitis of the Posterior Segment Treated with Intravitreal Sirolimus
4. PRM97 - New Modelling Approaches In Ophthalmology: Partitioned Vision Distrbution Model In Symptomatic Vitreomacular Adhesion (VMA)/Vitreomacular Traction (VMT) With Or Without Full-Thickness Macular Hole (FTMH)
5. PSS57 - Long-Term Visual Functioning Improvement is Associated with Resolution of Vitreomacular Adhesion in Subjects with Vitreomacular Traction, Including Macular Hole Treated with Intravitreal Ocriplasmin: Results From The Oasis Study
6. PSS52 - Use of Novel Health-Related Quality of Life Measures to Assess The Effect of Metamorphopsia Symptoms In Patients with Vitreomacular Traction, With or Without Macular Hole: The Memo Study
7. PSS25 - Prevalence of Metamorphopsia in Patients with Vitreomacular Traction, with or without Macular Hole, and its Impact on Quality of Life: The Memo Study
8. PSS34 - Visual Function Response To Ocriplasmin For The Treatment Of Vitreomacular Traction And Macular Hole
9. PSS22 - Ocriplasmin For The Treatment Of Vitreomacular Traction And Macular Holes: Long-Term Modelling Of Clinical And Economic Value Of Resolution Of Traction In France
10. PSS6 - Management Of Vitreomacular Traction (Vmt) By Vitrectomy In France: A Retrospective Hospital Database Analysis (Pmsi)
11. PSS4 - Visual Function And Anatomic Responses To Ocriplasmin
12. PSS5 - Baseline Patient, Ocular Features and Management of a Patient Population Diagnosed with Vitreomacular Traction: An Observational Study in Flanders
13. PSS3 - Baseline Characteristics and Vitreoretinal Interface Features in Patients with Vitreomacular Traction and Macular Hole from the MIVI-TRUST Clinical Program
14. PGI3 - Do you need to account for baseline viral load when assessing the relative efficacy of interventions for treatment naïve hbeag positive chronic hepatitis b (chb) patients? results from unadjusted and adjusted network meta-analyses (nma)
15. PRM141 Combining an Ordered Logit Model With Individual Patient-Level Data to Robustly Estimate Within-Category Visual Acuity Starting Distributions: An Innovative Modeling Approach in the Case of Vitreomacular Traction
16. PRM45 Utility Estimation for Visual Acuity Health States: An Original and Pragmatic Approach to Transpose Published Evidence Into a More Flexible Estimation
17. PIN80 Multivariate Cox Analysis Regarding Treatment Switch on Chronic Hepatitis B (CHB) Disease Management Based on a 2-Year Prospective Study in 5 European (EU) Countries
18. PIN47 The Humanistic and Economic Burden of Hepatitis C Across the United States, Europe, and Asia
19. PIN37 Cost-Effectiveness of Treatment Initiation With Ritonavir-Boosted Atazanavir (ATV/R) and Lopinavir (LPV/R) in Treatment-NaÏve HIV Patients at Different CD4 Levels at Baseline
20. 1103 THE EFFECT OF HEPATITIS C TREATMENT ON HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, AND HEALTHCARE RESOURCE USE AMONG PATIENTS IN EUROPE
21. 494 REAL-WORLD DATA ON TREATMENT MODIFICATION FROM A LONG-TERM OBSERVATIONAL STUDY OF CHRONIC HEPATITIS B PATIENTS FROM 5 EUROPEAN COUNTRIES
22. PGI3 Current Treatments for Chronic Hepatitis B: A Systematic Review
23. PIN73 Modeling the Long Term Clinical Outcomes and Health Care Cost Impact of Initiating Treatment with Atazanavir/R Compared with Darunavir/R, Lopinavir/R and Efavirenz for HIV-1 Infected Treatment-NaÏve Patients: Country Results for Italy, Spain, Portugal and UK
24. PIN89 Do Patients and Physicians Have Similar Preferences Chronic Hepatitis B Treatment Outcomes in Turkey?
25. PIN82 Cost-Effectiveness of Atazanavir/R Compared to Darunavir/R in Germany
26. PIN8 A Decision Tree Model Comparing Clinical Outcomes of Treatment with Telbivudine with or without “Tenofovir Add-on as Needed” and Lamivudine with or without “Tenofovir Add-on as Needed” in the Treatment of Chronic Hepatitis B Infection in Turkey
27. PIN6 Clinical Outcomes Analysis Comparing Entecavir with Lamivudine Monotherapy and Lamivudine with “Tenofovir Add-on as Needed” Approach in the Treatment of Chronic Hepatitis B Infection in Turkey
28. PIN3 Comparing the Efficacy and Tolerability of Anti-Retroviral Therapy in Treatment-Naïve HIV-1 Infected Adults: A Systematic review of Randomized Clinical Trials and Bayesian Mixed Treatment Comparisons Including Atazanavir/R, Darunavir/R, Lopinavir/R, and Efavirenz
29. PIN40 DO PATIENTS AND PHYSICIANS HAVE SIMILAR PREFERENCES FOR HEALTH CARE DECISIONS INVOLVING UNCERTAIN OUTCOMES FOR CHRONIC HEPATITIS B IN GERMANY AND TURKEY?
30. PIN79 IS IT POSSIBLE TO OBTAIN WILLINGNESS-TO-PAY ESTIMATES IN EUROPE? A VALIDITY TEST OF STATED PREFERENCES FOR HEPATITIS-B TREATMENTS
31. PIN63 PATIENT PREFERENCES FOR BENEFITS, RISKS, AND WEIGHT OF EVIDENCE ASSOCIATED WITH HEPATITIS B TREATMENTS
32. PGI13 MODELING THE LONG TERM CONSEQUENCES OF SUPPRESSING VIRAL REPLICATION IN CHRONIC HEPATITIS B: A COSTEFFECTIVENESS ANALYSIS OF ENTECAVIR (BARACLUDE®) IN TURKEY
33. 719 A CROSS-SECTIONAL ANALYSIS OF CHRONIC HEPATITIS B PATIENT CHARACTERISTICS AND CLINICAL MANAGEMENT PATTERNS IN GERMANY, POLAND, ROMANIA AND TURKEY
34. IN2 MODELING LONG-TERM MORTALITY AND MORBIDITY IMPACT WITH ENTECAVIR TREATMENT IN CHB PATIENTS IN BELGIUM
35. PSS62 - Improved Visual Function Is Associated With Inflammation Reduction In Subjects With Non-Infectious Uveitis (Niu) of The Posterior Segment Treated With Intravitreal Sirolimus: ResultsFrom Sakura Study 1
36. PMH7: A MARKOV COHORT SIMULATION ESTIMATING THE RISK OF DEVELOPING CORONARY HEART DISEASE IN PATIENTS USING ANTIPSYCHOTIC DRUGS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.